MENU
+Compare
RNAC
Stock ticker: NASDAQ
AS OF
Apr 3 closing price
Price
$12.34
Change
-$0.61 (-4.71%)
Capitalization
319.69M

RNAC Cartesian Therapeutics Forecast, Technical & Fundamental Analysis

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RNAC with price predictions
Apr 02, 2025

Momentum Indicator for RNAC turns negative, indicating new downward trend

RNAC saw its Momentum Indicator move below the 0 level on February 26, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In of the 89 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for RNAC turned negative on February 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

RNAC moved below its 50-day moving average on March 03, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RNAC crossed bearishly below the 50-day moving average on March 04, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RNAC entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAC advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .

RNAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RNAC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RNAC's P/B Ratio (588.235) is very high in comparison to the industry average of (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (5.777) is also within normal values, averaging (252.036).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

RNAC is expected to report earnings to fall 40.00% to -89 cents per share on May 09

Cartesian Therapeutics RNAC Stock Earnings Reports
Q1'24
Est.
$-0.90
Q4'23
Missed
by $1.47
Q3'23
Missed
by $1.28
Q2'23
Beat
by $0.01
Q1'23
Missed
by $4.11
The last earnings report on March 07 showed earnings per share of -150 cents, missing the estimate of -2 cents. With 83.67K shares outstanding, the current market capitalization sits at 319.69M.
A.I. Advisor
published General Information

General Information

a developer of targeted immunotherapies and vaccines to treat and prevent diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
704 Quince Orchard Road
Phone
+1 617 923-1400
Employees
38
Web
https://www.cartesiantherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NYVBX18.80N/A
N/A
Davis NY Venture B
MSCRX10.55N/A
N/A
Madison Small Cap R6
MSGNX5.92N/A
N/A
MassMutual Small Cap Gr Eq R3
RYUIX60.00N/A
N/A
Rydex Utilities Inv
BIOUX45.58N/A
N/A
Baron Opportunity R6

RNAC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with SNPX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then SNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-4.71%
SNPX - RNAC
91%
Closely correlated
-4.22%
ALLR - RNAC
86%
Closely correlated
-7.03%
NRXP - RNAC
86%
Closely correlated
-5.97%
PALI - RNAC
81%
Closely correlated
-3.54%
HRTX - RNAC
36%
Loosely correlated
-4.04%
More

Groups containing RNAC

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-4.71%
RNAC
(6 stocks)
68%
Closely correlated
-5.34%